## CRL: Charles River Laboratories International, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.7% below STRENGTH zone (3.0-6.0%); RSI 71 overbought. Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.7% MRS), overbought RSI (71).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($191.12)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Backbone of Discovery: A Deep Dive into Charles River Laboratories (CRL)**
- Source: FinancialContent | 20251223T101000 | Somewhat-Bullish | Relevance: 100%
- Charles River Laboratories (CRL) is an indispensable backbone of the global pharmaceutical industry, participating in the development of over 80% of FDA-approved drugs in the last five years. After a tumultuous period, CRL is undergoing a strategic realignment with a $1 billion buyback program and a pivot towards AI-driven discovery, aiming to evolve into a high-tech drug development powerhouse. The company's business model spans Discovery and Safety Assessment, Research Models and Services, and Manufacturing Solutions, with its stock recovering in 2025 due to regulatory resolutions and a focus on shareholder returns.

**2. Charles River Laboratories (CRL): Valuation Check After SEC Clearance and BofA Upgrade Lift the Stock**
- Source: Simply Wall Street | 20251223T090801 | Somewhat-Bullish | Relevance: 100%
- Charles River Laboratories (CRL) recently saw its stock climb about 3% after the U.S. SEC closed its investigation without enforcement action and BofA Securities upgraded the company. This relief rally adds to significant recent momentum, though a Simply Wall St narrative suggests the stock is 7.5% overvalued with a fair value of $188.93, while market ratios offer a different perspective.

**3. Charles River Laboratories stock hits 52-week high at $200.96 By Investing.com**
- Source: Investing.com Nigeria | 20251222T150819 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. (CRL) reached a new 52-week high of $200.96, reflecting a 7.25% positive change over the past year and a 33.65% 6-month price return. Despite current losses, analysts forecast profitability for FY2025, with several firms upgrading their ratings and price targets for the company.

**4. Charles River Laboratories stock hits 52-week high at $200.96**
- Source: Investing.com | 20251222T150801 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. (CRL) stock has reached a new 52-week high of $200.96, reflecting a 7.25% positive change over the past year and outperforming with a 33.65% 6-month price return. Despite current losses, analysts forecast profitability for FY2025 with an EPS of $10.34, and the company has received multiple analyst upgrades and has concluded an SEC investigation with no enforcement action. This upward trajectory signals strong market interest and potential future gains for the pharmaceutical and biotechnology sector company.

**5. Charles River Laboratories stock hits 52-week high at $200.96 By Investing.com**
- Source: Investing.com Canada | 20251222T150634 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. (CRL) has reached a new 52-week high of $200.96, reflecting a 7.25% positive change over the past year and a 33.65% 6-month price return. This surge comes amidst analyst upgrades and a concluded SEC investigation without enforcement action, indicating strong market confidence and potential for future growth in the pharmaceutical and biotechnology industries.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $200 | $174 | +15% |
| 2025-12-15 | Barclays | $215 | $210 | +2% |
| 2025-12-15 | JP Morgan | $190 | $165 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 18.5x stretched relative to 7% growth. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 1.64 |
| 52W Range | $91.86 - $204.47 |
| Short Interest | 6.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 18.5 |
| Current P/E | 19.8 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 5.4% to 1.7% (-3.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.3pp (needs >3.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.15), confirming momentum. RSI overbought at 71, risk of mean reversion. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.71% (CS: 90) | Neutral |
| RSI_14 | 70.7 | Overbought |
| MACD Histogram | 1.15 | Bullish |
| vs SMA20 | 1.073x | Above |
| vs SMA50 | 1.121x | Above |
| vs SMA200 | 1.287x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $202.82
- **Stop Loss:** $191.12 (5.8% risk)
- **Target:** $214.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 102
- **Position Value:** $20,687.64
- **Portfolio %:** 20.69%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*